Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis

Halina Offner, Bente Danneskiold-Samsøe, Paula Dore-Duffy

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

Original languageEnglish (US)
Pages (from-to)159-167
Number of pages9
JournalClinical Immunology and Immunopathology
Volume22
Issue number2
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Rosette Formation
Aspirin
Multiple Sclerosis
Prostaglandins
Lymphocytes
Alprostadil
Prostaglandins E
Dinoprostone
Rheumatoid Arthritis
Population

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis. / Offner, Halina; Danneskiold-Samsøe, Bente; Dore-Duffy, Paula.

In: Clinical Immunology and Immunopathology, Vol. 22, No. 2, 1982, p. 159-167.

Research output: Contribution to journalArticle

@article{72f5b70822654aa7bff36e6dfd196ce5,
title = "Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis",
abstract = "Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.",
author = "Halina Offner and Bente Danneskiold-Sams{\o}e and Paula Dore-Duffy",
year = "1982",
doi = "10.1016/0090-1229(82)90034-4",
language = "English (US)",
volume = "22",
pages = "159--167",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis

AU - Offner, Halina

AU - Danneskiold-Samsøe, Bente

AU - Dore-Duffy, Paula

PY - 1982

Y1 - 1982

N2 - Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

AB - Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

UR - http://www.scopus.com/inward/record.url?scp=0020082448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020082448&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(82)90034-4

DO - 10.1016/0090-1229(82)90034-4

M3 - Article

C2 - 6286189

AN - SCOPUS:0020082448

VL - 22

SP - 159

EP - 167

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -